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(bemiparin) into polymeric nanoparticles obtained from
cationic block copolymers: properties and cell activity†
Felisa Reyes-Ortega,*a Gema Rodr´ıguez,a Mar´ıa Rosa Aguilar,a Megan Lord,c
John Whitelock,c Martina H. Stenzelb and Julio San Roma´na
Bemiparin (fractionated low molecular weight heparin)-loaded nanoparticles were prepared by two
consecutive w/o emulsions and an inversion to an o/w emulsion for various polymer systems as
controlled release formulations. New synthetic block copolymers, poly(methyl methacrylate-b-trimethyl
aminoethyl methacrylate) (PMMA-b-PMAETMA), with controlled microstructure and molecular weight,
were prepared by RAFT (Reversible Addition-Fragmentation chain-Transfer) polymerization creating a
set of polymers with diﬀerent amounts of cationic charges. For comparison, a non-biodegradable
positively charged polymer, Eudragit RS PO, and a biodegradable polymer poly(lactic-co-glycolic acid),
PLGA, were used. The microstructural arrangement of MMA and MAETMA sequences in PMMA-b-
PMAETMA results in self-assembled core–shell nanoparticles in water with a positively charged surface,
which interacts with bemiparin. The formulations were evaluated in terms of particle size, zeta potential
and morphology by scanning electron microscopy (SEM). The entrapment of bemiparin molecules was
conﬁrmed by a negatively increased zeta potential value and the detection of a sulfur signal by energy
dispersive X-ray spectroscopy (EDAX). High encapsulation eﬃciency was reached with all the polymeric
matrices, ranging from 89 to 98%. Systems prepared with synthetic block copolymers PMMA-b-
PMAETMA and PLGA showed higher in vitro bemiparin release than Eudragit RS PO systems. For each
formulation, bemiparin released from nanoparticles preserved its biological activity as shown by the
BaF32 cell proliferation assay in the presence of ﬁbroblast growth factor (FGF2).Introduction
Polymeric nanoscale drug delivery systems are attractive for the
therapeutic delivery of drugs to target tissues. Heparin (HP) is a
highly sulphated and negatively charged glycosaminoglycan
formed by a or b (1–4) linked uronic acid (90% a-L-iduronic acid,
10% b-D-glucuronic acid) and a-D-glucosamine residues that
present several biological functions including anticoagulation,
and an interesting regulation role of growth factor activity,
including those of broblast growth factors (FGFs) and vascular
endothelial growth factors (VEGFs).1 Its pharmacological
activity has been demonstrated in many diseases such as
asthma, allergic rhinitis, inammatory bowel disease, vascularience and Technology (ICTP-CSIC), Spain
ter in Bioengineering, Biomaterials and
ierva 3, 28006 Madrid, Spain. E-mail:
5644853; Tel: +34 91 5618806 ext. 332
esign, School of Chemical Sciences &
ales, Sydney, NSW, Australia 2052
g, The University of New South Wales,
tion (ESI) available. See DOI:
–860disorders,2–4 and has recently been shown to provide anti-
angiogenic properties.5
Unfractionated heparin (UFH) is polydisperse while low
molecular weight heparins (LMWH), such as bemiparin
(HIBOR), are obtained by the chemical b-elimination depoly-
merization of UFH6 with a molecular weight of less than 8 kDa.
LMWHs contain a precisely dened disaccharide composition
with a higher eﬃcacy safety ratio due to the better dened anti-
Xa/anti-IIa ratio that reduces heparin side eﬀects, including
problems of coagulation and bleeding. Heparin is administered
systemically, due to the lack of absorption when administered
orally and its instability at acidic pH. Additionally it has a short
half-life in vivo. Research has been performed on using the
biological and chemical properties of heparin to develop more
eﬃcient administration methods to decrease side eﬀects asso-
ciated with repeated HP injections, such as HP-induced
thrombocytopenia, osteoporosis and alopecia. To facilitate drug
permeation, evade proteolytic degradation and prolong intes-
tinal retention time, to ultimately improve the oral bioavail-
ability of HP, hydrogels and particulate carrier systems have
been recently developed.7
Potential pathways for the delivery of heparin include chemical
conjugation,3,8 encapsulation into a hydrogel,9 processing into aThis journal is ª The Royal Society of Chemistry 2013
Fig. 1 Chemical structures of the amphiphilic block copolymers prepared by
RAFT polymerization (PMMAn-b-PMAETMAm) and the two commercial polymers,
Eudragit RS PO and PLGA used as bemiparin carriers.
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View Article Onlinepolymer matrix,10 or binding it to a carrier by electrostatic
forces.10c,11 Composite materials with heparin were oen investi-
gated as hemocompatible coatings,12 but also gels for subcuta-
neous injections,8a–c micro- and nanoparticles8e,10c,11,13 or
electrospun ber mats10a were the center of attention. Most
applications are targeted at the use of heparin as an anti-coagulant,
but the use in cancer treatment is of increasing interest.9b,11,14
Nanoparticles (NPs) are attractive due to their potentially
long circulation time and the possibility to be endocytosed by
cells. The use of nanoparticles as drug carriers has been
preferred in delivering biologics because when they are loaded
with an adjuvant that aids the absorption, they can be simul-
taneously localized at the site of absorption with the drugs. NPs
allow HP protection from degradation while the drug can be
slowly released from the particles in an unaltered state.15Ubrich
and co-workers showed previously that LMWH can be encap-
sulated into a range of NPs based on either biodegradable poly-
3-caprolactone and PLGA or positively charged nonbiodegrad-
able polymethacrylates, Eudragit RS and RL microparticles.16
A sequential w/o and o/w emulsifying technique was employed
to generate these LMWH loaded microparticles either using the
polymer alone or a blend of polymers.16b The highest encapsu-
lation eﬃciencies obtained in both studies were 39–47%. The
LMWH release was limited to 20–30% when Eudragit RS PO
either alone or in combination with PCL or PLGA was used,
possibly due to the strong ionic interactions between the drug
and the polycationic polymer. These particles were then used
for oral administration of heparin-loaded NPs in rabbits. Each
formulation increased the anti-factor Xa activity.16a These
particles displayed high bioavailability of heparin in vivo,
probably by overcoming the slow absorption of the negatively
charged heparin.17
Inspired by these promising results, we center the attention
on the application of cationic acrylic polymers of well dened
microstructure, charge and low polydispersity, prepared by
Reversible Addition-Fragmentation chain-Transfer (RAFT)
polymerization, and for comparison the biodegradable and
non-charged polymer, poly(lactic-co-glycolic acid) (PLGA)18 and
a non-biodegradable and polycationic polymer (Eudragit RS
PO)19 to encapsulate bemiparin, ultra-LMWH with an average
molecular weight of 3600 g mol1.
RESOMER RG 504 H is a biocompatible, neutral and biode-
gradable random copolymer of lactic and glycolic acids (PLGA)
with equimolecular monomer composition obtained by ring-
opening polymerization (Fig. 1). It is a common choice in the
formulation of nanoparticles due to its biological and
biochemical properties.13a,20,21 Electrostatic forces with bemi-
parin are absent and the drug is packed into the polymer matrix
during processing without additional driving force.
This is in contrast to Eudragit RS PO, a non-biodegradable
random polycationic synthetic polymer, widely used in the
formulation of drug delivery systems and more specically in
nanoparticle formulations due to its mucoadhesive character-
istics.22,23 It is based on poly(ethyl acrylate-co-methyl methacry-
late-co-trimethyl aminoethyl methacrylate) poly(EA-co-MMA-co-
MAETMA) (1 : 2 : 0.1) and is insoluble at acidic and physiolog-
ical pH, but swells at basic pH.24This journal is ª The Royal Society of Chemistry 2013The synthetic polymer was inspired by the structure of
Eudragit RS PO, which is based on methyl methacrylate
(MMA) (and some ethyl acrylate) and trimethyl aminoethyl
methacrylate (MAETMA), but with well dened microstructure
and morphology.
Block copolymers based on PMMA-b-PMAETMA were
prepared by RAFT polymerization, an easy and versatile poly-
merization technique that allows the synthesis of macromole-
cules with a strictly controlled chemical structure using mild
reaction conditions25,26 (Fig. 1). The composition of the cationic
monomer was varied between 0.02 and 0.1 molar ratios in order
to obtain well dened block copolymers with diﬀerent lengths
of the cationic PMAETMA segment (diﬀerent charge densities).
Variation of the amount of cationic charges, which will bind to
HP via electrostatic forces, will modulate encapsulation eﬃ-
ciency and release, thus altering the biological activity.
Biological activity and stability of the prepared bemiparin
loaded nanoparticles were analyzed for these copolymer systems.
Nanoparticles based on Eudragit RS PO and RESOMER RG 504
H were then used as control systems. HP has been shown to
stabilize and protect growth factors, including diﬀerent isoforms
of broblast growth factor (FGF) and vascular endothelial growth
factor (VEGF), from degradation and at the same time increase
the aﬃnity of the complex to cell receptors.1a,c,d,27 In this work, the
biological activity of bemiparin nanoparticles was evaluated
using BaF32 cells expressing the FGF receptor 1c, which interacts
with FGF2. This in vitro model provides information about the
bemiparin capacity to form the ternary system (bemiparin-FGF-
FGFR-1c) that triggers proliferation in these cells.28,29J. Mater. Chem. B, 2013, 1, 850–860 | 851
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View Article OnlineExperimental
Materials
The Low Molecular Weight Heparin (LMWH) used was bemiparin
(111.3 UI mg1, 5500 Da) and was kindly donated by ROVI
PHARMACEUTICALS LABORATORIES (Madrid, Spain). Eudragit
RS PO (mean Mw: 150 000 Da) was purchased from Degussa
(European Pharmacopoeia). PLGA 50 : 50 molar ratio (mean Mw:
40 000 Da) (RESOMER RG 504 H) was supplied by Boehringer
Ingelheim Pharma GmbH & Co. Polyvinylalcohol used as a
surfactant (PVA, Mw: 31 000–50 000 Da, 87–89% hydrolyzed) was
purchased from Sigma. Methyl methacrylate (MMA) (Acros
Organics) and [2-(methacryloyloxy)ethyl]trimethylammonium (80%
aqueous solution) (MAETMA) (Sigma-Aldrich) were puried by
passing the monomer over a column with basic aluminium oxide.
2,20-Azobisisobutyronitrile (AIBN, Merck) was recrystallized from
methanol. 4,40-Azobis (4-cyanovaleric acid) (V501) (Sigma-Aldrich),
ethyl acetate (Sigma-Aldrich) purity grade >99.5%, dimethyl
disulfoxide (SCHARLAB) purity grade >98% and HEPES minimum
99.5% titration (Sigma-Aldrich) were used as received.Cell culture reagents
Recombinant human broblast growth factor-2 (FGF-2) (Invi-
trogen) was used without further purications. Dye CellTiter
96 Aqueous One Solution Reagent (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS)) (Promega) was also used as received. BaF32
cells are an IL-3-dependent and HP sulphate proteoglycan
decient myeloid B cell line that has been stably transfected
with FGF receptor 1c (FGFR-1c). BaF32 cells represent a model
system developed to identify HP/heparan sulphate structures
that interact with FGFs and their receptors to form active
ternary complexes.28,29 An RPMI 1640 powder culture medium
(Sigma-Aldrich) was supplemented with 2 g L1 sodium bicar-
bonate (Sigma-Aldrich, 99–100% purity, suitable for cell
culture), 10% (v/v) fetal bovine serum (FBS) (Gibco), a 1% (v/v)
penicillin–streptomycin mixture (Gibco), and the conditioned
medium was stored at 20 C until it was required.Methods
Preparation of block copolymers by RAFT polymerization.
The RAFT agent, 4-cyanopentanoic acid dithiobenzoate
(CPADB), used to carry out the MMA polymerization was
synthesized as reported by Y. Mitsukami et al.30 The PMMATable 1 Block copolymer system composition and mean molecular weight distribu
the presence of a PMMA970 macro RAFT agent in DMSO at 70 C [macroRAFT] ¼ 0.1
the molar composition percentage of each segment in the block copolymer system
[MAETMA] : [PMMA
macroRAFT]
% Conversion
aer 6 h Mn,theo
Mn,exp
(measured by S
[100] : [1] 67 69 000 66 000
[50] : [1] 60 61 200 64 000
[25] : [1] 56 57 900 56 000
a Unit composition of the block copolymer systems were calculated by 1H-N
4.2–4.4 ppm integration peak for PMAETMA.
852 | J. Mater. Chem. B, 2013, 1, 850–860macroRAFT agent was prepared by bulk radical polymerization,
dissolving 1.64 mg AIBN (0.01 mmol) and 28 mg CPADB (0.1
mmol) in 10.6 mL of MMA (100 mmol). Five replicate samples
were prepared and degassed by bubbling nitrogen N2 (g)
through the solution for 40 min. All samples were heated at 60
C for 2, 4, 6, 21 and 24 h, respectively. The conversions were
determined gravimetrically and by 1H-NMR.
A series of block copolymers of diﬀerent poly(MAETMA)
sequence lengths were prepared using the same PMMA mac-
roRAFT agent (Mw(GPC) ¼ 55 000 g mol1, Mw/Mn(GPC) ¼ 1.24).
These block copolymers were labelled as PMMAn-b-PMAETMAm
(Fig. 1) where n and m are the number-average degrees of
polymerization (DP) of PMMA and PMAETMA blocks calculated
from 1H-NMR (Table 1).
The block copolymers were prepared dissolving 6.2 mL of a
0.6 mM PMMA stock solution in DMSO (3.74 mmol) with 1.8 mL
of a 0.42 mM 4,40-azobis(4-cyanovaleric acid) (V501) stock
solution in a DMSO solution (0.76 mmol) and diﬀerent amounts
of MAETMA (80% aqueous solution) (374, 187 and 93.5 mmol
respectively) in 34 mL DMSO. Samples were sealed, degassed by
purging nitrogen for 30 min through the solution and heated in
an oil bath (70 C) for 6 h. The conversion was determined by
1H-NMR using DMSO-d6 as the solvent. The block copolymers
were puried by dialyzing for three days against water, using
cellulose tubular membranes (Spectrum Laboratories, molec-
ular weight cut-oﬀ: 3.5 kDa).
Characterisation techniques. Bemiparin molecular weight
distribution (Mw ¼ 5500, PDI ¼ 1.08) was measured by Size
Exclusion Chromatography, SEC. Aqueous size exclusion chro-
matography was implemented using a Shimadzu modular
system comprising a DGU-20A3 solvent degasser, a LC-20AD
pump, a CTO-20A column oven, a SIL-20A HT autosampler, RID-
10A refractive index detector, and an SPD-20A Shimadzu UV-VIS
detector (ow rate: 1 mL min1, temperature: 37 C). The
instrument was equipped with three columns (300 mm  7.5
mm, 8 mm): PL-aquagel-OH 30, PL-aquagel-OH 40 and PL-
aquagel-OH 50, protected with a guard column (50 mm  7.5
mm, 8 mm) of the same material (Polymer Laboratories). Cali-
bration was performed with polysaccharide standards (Pullulan
Polysaccharide, PL2090-0100 VARIAN) ranging from 180 to
708 000 g mol1. The eluent solvent used was milli-Q water
adjusted to pH 3 with a 0.2 M NaNO3, 0.01 M NaHPO4 and 1 M
acetic acid aqueous solution.
Number and weight averagemolecular weights of PMMA and
block copolymers were determined by SEC in a Perkin-Elmertion measured by NMR and SEC respectively, for the polymerization of MAETMA in
g mol1, [V501] ¼ 0.02 g mol1, [MAETMA] ¼ 10, 5 or 2.5 g mol1. F is deﬁned as
EC) PDI
PMMA
units (n)
PMAETMA
units (m)
FPMMA/FPMAETMA
(calculated by NMR)a
1.40 970 158 86/14
1.41 970 84 92/8
1.45 970 20 98/2
MR using the 0.3–1.2 ppm integration peak for PMMA + PMAETMA and
This journal is ª The Royal Society of Chemistry 2013
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View Article Onlineapparatus equipped with an isocratic pump serial 200 con-
nected to a diﬀerential refractometric detector (serial 200a).
Two Resipore columns (Varian) were conditioned at 70 C and
used to elute the samples (1 mg mL1 concentration) at 0.3 mL
min1 HPLC-grade N,N0-dimethylformamide (DMF) supple-
mented with 0.1% v/v LiBr. Calibration of SEC was carried out
with monodisperse standard poly(methyl methacrylate)
samples in the range of 2.9 103 to 480 103 Da obtained from
Polymer Laboratories with a sample injection volume of 20 mL.
1H- and 13C-NMR spectra were recorded on a Mercury 400BB
spectrometer, operating at 400 and 133.3 MHz, respectively. The
spectra were recorded by dissolving the corresponding sample
in deuterated dimethylsulfoxide (DMSO-d6), chloroform
(CDCl3) or deuterium oxide (D2O).
Copolymerisation reactions were performed inside the NMR
equipment to determine the kinetic parameters. These experi-
ments were carried out at 70 C with a pulse sequence of 7 ms
equivalent to a 90 tip angle, a 60 s delay time, a spinning rate of
7 Hz, and one acquisition (FID), nt ¼ 1, for each datum.
Nanoparticle preparation. The preparation of nanoparticles
was carried out by the emulsion technique previously
described31 and modied as follows: 1 mL of the aqueous
bemiparin solution (2% w/v) was rst emulsied during the
addition of 10 mL of each polymer solution in ethyl acetate (1%
w/v). The resulting water-in-oil emulsion was thereaer mixed
by sonication for 1 min with a 2% PVA aqueous solution (40
mL), involving the inversion to an o/w emulsion. Aer evapo-
ration of ethyl acetate under reduced pressure, the nano-
particles were isolated by centrifugation (12 000 rpm for 20 min
at 25 C). Aer three cycles (washing with deionized water and
then centrifugation) to remove the PVA, the supernatants from
the previous centrifugation steps were pooled for free drug
measurement and drug entrapment eﬃciency evaluation. Aer
the nal centrifugation, nanoparticles were resuspended in
water as a colloidal suspension and freeze-dried.
Size distribution, zeta potential and morphology. The core–
shell morphology of nanoparticles was analyzed by scanning
electron microscopy (SEM) using a Philips XL 30 ESEM appa-
ratus at an accelerating voltage of 15 keV. It was equipped with a
eld emission Hitachi SU800 apparatus. The samples were
prepared by deposition of the corresponding nanoparticle
suspension (0.01 mg mL1) over small glass disks (13 mm
diameter and 1 mm thickness), and the solvent (H2O) was
evaporated at room temperature for 24 h. All the samples were
coated with chrome prior to examination by SEM. Surface
chemical characteristics were analyzed by Energy Dispersive X-
ray analysis (EDAX). The evidence of bemiparin encapsulation
and surface chemical characteristics were detected by energy
dispersive X-ray analysis (EDX). Zeta potential and particle size
distribution were evaluated with a Zetasizer NanoZS (Malvern
Instruments, UK) equipped with a He–Ne laser beam with a
wavelength of 633 nm and a scattering angle of 173. The zeta
potential measurements were performed in disposable folded
capillary cells (DTS1060, Malvern Instruments) and particle-
size measurements in square polystyrene cuvettes (DTS0012,
Malvern Instruments) with 0.01 mg mL1 aqueous solutions at
25 C.This journal is ª The Royal Society of Chemistry 2013Hydrodynamic diameter (Dh) and polydispersity index were
determined by dynamic light scattering (DLS). The intensity of
light scattered was used to calculate the mean hydrodynamic
diameter (Z-average mean), based on the Stokes–Einstein
equation, assuming the particle to be spherical. The nano-
particle suspension (0.01 mg mL1) was prepared in a 25 mM
HEPES buﬀer. For each sample, the statistical average and
standard deviation (SD) of data were calculated from at least ve
measurements.
Zeta potential analysis was carried out using laser doppler
electrophoresis (LDE) with 20 runs per measurement. The zeta
potentials were automatically calculated from the electropho-
retic mobility using Smoluchowski's approximation:
UE ¼ 23zf(ka)/3h/ z z UEh/3
This approximation is generally applied when the measure-
ments are carried out in aqueous media and considers that
Henry's function takes a value of 3/2. Where UE ¼ electro-
phoretical mobility, z ¼ zeta potential, 3 ¼ dielectric constant, h
¼ viscosity, and f(ka) ¼ Henry's function.
Diﬀerential Scanning Calorimetry (DSC). Glass transition
temperatures (Tg) were measured by DSC with a Perkin Elmer
DSC7 interfaced to a thermal analysis data system TAC 7/DX.
The dry samples (10–15 mg) were placed in aluminium pans
and heated from20 to 180 C at a constant rate of 10 Cmin1.
Tg was taken as the midpoint of the heat capacity transition.
Bemiparin encapsulation eﬃciency. The drug encapsulate
eﬃciency (EE) was determined by high performance liquid
chromatography (HPLC) using a SHIMADZU SIL-20 equipment
with UV-Vis detection at 242 nm. The mobile phase was 1% (w/
v) acetic acid in milli-Q water and measurements were carried
out at 37 C and 1 mL min1. The amount of non-entrapped
drug recovered in the external aqueous phase aer centrifuga-
tion was quantied using a calibration curve obtained from
diﬀerent solutions of known concentration, by integration of
the peak at 2.3 min  0.15 min. The percentage of EE was
dened as:
%EE ¼ ([bemiparin]o  [bemiparin]i)/[bemiparin]o  100
where [bemiparin]o is the total added bemiparin amount and
[bemiparin]i is the non-encapsulated bemiparin amount.
Bemiparin release. Drug release from NPs was evaluated in
PBS (saline phosphate buﬀer: pH 7.4, 0.01 M; NaCl: 0.15 mol
L1). For this purpose, 10 mg of loaded bemiparin NPs were
suspended in 5 mL of PBS and incubated at 37 C under gentle
magnetic stirring. At various time intervals, 0.5 mL sample was
withdrawn and replaced by 0.5 mL of fresh buﬀer. These
aliquots of 0.5 mL were centrifuged at 12 000 rpm for 15 min
and supernatants were analysed by HPLC (SHIMADZU SIL-20) at
242 nm to determine the amount of bemiparin released. The
pellet was placed in the original nanoparticle suspension with
the fresh buﬀer replaced. A calibration curve of bemiparin was
obtained previously from solutions of known concentration in
the same medium, by measuring the integration of a peak at 2.3
min  0.15 min.J. Mater. Chem. B, 2013, 1, 850–860 | 853
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View Article OnlineBaF32 cell proliferation assay. The BaF32 cell proliferation
assay was used to determine the activity of the bemiparin
released from the polymer systems. The readout of this assay
was cell proliferation which indicated the biological activity of
free and encapsulated bemiparin by the formation of ternary
complexes on the cell surface. BaF32 cells were maintained in
an RPMI 1640 medium containing 10% (v/v) FBS, 10% (v/v)
WEHI-3BD conditioned medium, and a 1% (v/v) penicillin–
streptomycin mixture. WEHI-3BD cells were maintained in an
RPMI 1640 medium supplemented with 2 g L1 sodium bicar-
bonate, 10% (v/v) FBS, and a 1% (v/v) penicillin–streptomycin
mixture, and the conditionedmediumwas collected three times
per week and stored at 20 C until it was required. For the
mitogenic assays, the BaF32 cells were transferred into IL-3
depleted medium for 24 h prior to experimentation and seeded
into 96-well plates at a density of 8  104 cells per well in the
presence of free bemiparin or encapsulated bemiparin at
diﬀerent concentrations and with and without FGF2 (0.03 nM).
Cells in the presence of a medium without any treatment were
used as a negative control. Cells were incubated for 72 h in 5%
CO2 at 37 C, and the number of viable cells was assessed using
the MTS assay. The MTS reagent was added to the cell cultures 6
h prior to measurement of the absorbance at 490 nm. Cell
proliferation was assayed by measuring the increase of absor-
bance, which corresponded to the cell number. To compare the
diﬀerence between the free and encapsulated bemiparin,
analysis of variance (ANOVA) of the results was carried out using
p < 0.05 signicance level.Fig. 3 1H-NMR spectra of PMMA970-b-PMAETMA84 block copolymers in
DMSO-d6.Results and discussion
Synthesis of block copolymers
RAFT polymerization is a versatile way to access block copoly-
mers, especially considering the robustness of the process in
the presence of many functional groups.26,32–34 Inspired by the
structure of Eudragit RS PO, the block copolymers were based
on PMMA segments while the second block was obtained from
trimethyl aminoethyl methacrylate. Controlled molecular
weight PMMA was synthesized using CPADB as the RAFTFig. 2 (a) Time vs. conversion of the polymerization of MAETMA in the presence of a
Molecular weight evolution of PMMAn-b-PMAETMAm block copolymers with the con
conversion  Mmonomer + MmacroRAFT37 (lines). Data are presented as mean  SD (n
854 | J. Mater. Chem. B, 2013, 1, 850–860agent,35 which followed the expected living polymerization
(ESI†). The polymerization of the second monomer, MAETMA,
in the presence of a poly(methylmethacrylate) macroRAFT agent
leads to chain extension and therefore to the formation of an
amphiphilic block copolymer PMMA-b-PMAETMA. In an ideal
RAFT polymerization, the molecular weight of the block
copolymer and the ratio of both blocks can theoretically be
predicted using the ratio of concentration of monomers, the
thiocarbonylthio derivative concentration and the monomer
conversion of the polymerization.36
PMMA with Mw(GPC) of 55 000 g mol
1 (PDI ¼ 1.24) was
initially prepared and was employed as a macroRAFT agent in
DMSO at 70 C using three diﬀerent ratios of MAETMA to thi-
ocarbonyl thio functionalities (100 : 1, 50 : 1 and 25 : 1) for
chain extension. Aliquots were taken at two and six hours and
the conversion was analysed by 1H-NMR (Fig. 2a). The rate of
polymerization increased with increasing monomer concen-
tration. Themolecular weight distribution of the resulting block
copolymers increased linearly with conversion (Fig. 2b). The
polydispersity index ranged between 1.40 and 1.45, whichPMMA970macroRAFTagent using various ratios of [MAETMA] to [macroRAFT]. (b)
version (symbols), theoreticalMn calculated using the formula [M]/[macroRAFT]
¼ 3).
This journal is ª The Royal Society of Chemistry 2013
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View Article Onlineindicated a narrow molecular weight distribution of the
resulting block copolymers (Table 1), and therefore this
suggests that the transfer of the radical to the macroRAFT agent
was successful. For further conrmation of the formation of
block copolymers, the polymers were puried using dialysis
against water to remove unreacted MAETMA. The polymers
obtained aer a polymerization time of 6 hours were puried,
freeze-dried and analysed by 1H-NMR to determine the
composition (Fig. 3).
Table 1 summarizes the characteristics of the AB diblock
copolymers prepared, their targeted and measured molar
compositions, and Mn and polydispersity index.Fig. 4 Nanoparticle formation scheme prepared by an emulsion technique
using the block copolymers obtained via RAFT. (a) Preparation of non-loaded
polymeric nanoparticles and (b) preparation of loaded nanoparticles with bemi-
parin. A TEM image of the NP system 86/14 PMMA-b-PMAETMA obtained with a
ﬁeld emission Hitachi SU8000 apparatus is added.Preparation of nanoparticles (NPs)
Bemiparin is subject to degradation if not protected by a drug
delivery system. Therefore diﬀerent drug delivery systems were
investigated. PLGA does not bind to bemiparin and encapsu-
lation of bemiparin occurs only via packing during the emul-
sion process. Eudragit RS PO with its positive charges binds to
the negatively charged bemiparin. The cationic charges
provided by the MAETMA units are randomly distributed along
the non-degradable P(EA-MMA-MAETMA) random copolymer
chain; therefore the polymer cannot be dissolved in an aqueous
solution. Block copolymers based on the same building blocks
listed in Table 1 can in contrast form stable micellar nano-
aggregated systems, which in physiological uids can slowly
disaggregate to give small micelles that in a period of time
would be resolved.
Amphiphilic block copolymers are known to undergo self-
organization into micelles,34 which would be suitable as drug
carrier systems. Light scattering studies not only conrm the
formation of micellar aggregates but also reveal their sizes. All
block copolymers prepared were analysed using DLS aer
dispersion of the block copolymers in DMF and in water. Since
the particle size can be inuenced by the concentration, all the
samples were measured at a constant concentration of 3 mg
mL1 at 25 C. All the block copolymers showed a tendency to
formmultimicellar aggregates depending on the solvent. DLS of
the copolymer samples aer a ne dispersion in water shows
that the average size of aggregates in water increases with the
increasing of the length of the PMAETMA block (Table 2).
However, the average size indicates the relatively high tendency
toward the formation of multimicellar aggregates. When DMF
is used as the dispersion medium, the hydrodynamic diameter
(Dh) is much smaller than that in water, indicating that the
block copolymer has a clear tendency toward the formation of a
unimicellar system. Block copolymers were soluble in ethyl
acetate where micelle formation was absent.Table 2 Hydrodynamic diameter (Dh) of block copolymer systems measured by D
Sample Composition Dh (DMF) (nm) 
86/14 PMMA970-b-PMAETMA158 14.01  0.08
92/8 PMMA970-b-PMAETMA84 16.54  0.19
98/2 PMMA970-b-PMAETMA20 18.22  0.77
This journal is ª The Royal Society of Chemistry 2013The block copolymer PMMA-b-PMAETMA was soluble in ethyl
acetate for any composition and concentration interval used in
this work and when a diluted solution was added to water at high
stirring, a self-organised micelle dispersion was formed. Depic-
ted in Fig. 4a, the micelle nanoparticles have a core–shell orga-
nisation with the more hydrophobic MMA blocks in the core and
the hydrophilic MAETMA sequences in the shell. According to
the light scattering results, these micelles are not stable enough
in water and tend to aggregate in multimicellar nanoparticles
with a clear charged hydrophilic surface (Table 3).LS with a Zetasizer NanoZS (Malvern Instruments, UK) using diﬀerent solvents
SD Dh (H2O) (nm)  SD Dh (ethyl acetate) (nm)
143  18 Not detected
135  27 Not detected
132  12 Not detected
J. Mater. Chem. B, 2013, 1, 850–860 | 855
Table 3 Mean hydrodynamic diameters (nm) and zeta potential values (mV) of
the nanoparticle systems measured by DLS with a Zetasizer NanoZS (Malvern
Instruments, UK) after precipitation from ethyl acetate solutions
Sample Dh (nm)  SD ZP (mV)  SD
98/2 NPs 202  25 14  3
92/8 NPs 165  20 29  4
86/14 NPs 123  14 39  2
Eudragit RS PO NPs 284  42 20  2
PLGA NPs 121  5 14  1
Bemiparin loaded 98/2 NPs 105  12 28  1
Bemiparin loaded 92/8 NPs 144  21 14  1
Bemiparin loaded 86/14 NPs 198  17 10  3
Bemiparin loaded Eudragit RS PO NPs 142  20 32  2
Bemiparin loaded PLGA NPs 117  13 37  2
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View Article OnlineThe addition of bemiparin was carried out by a two step
emulsion process as shown in Fig. 4b. The rst step was the
preparation of bemiparin loaded micelles by adding a diluted
solution of bemiparin in water to the solution of the block
copolymer in ethyl acetate under vigorous stirring. This results
in the formation of very small micelles with the hydrophilic
ionized bemiparin in the core of the micelle, whereas in the
outer part are concentrated the more hydrophobic copolymer
sequences. With this arrangement, the formation of bridges is
easy by ionic interactions of the sulphate groups of bemiparin
and the ammonium ions of the PMMA-b-PMAETMA block
copolymer, with this characteristic distribution of micro-
domains. In a second step, this water in oil emulsion is added to
a diluted solution of poly(vinyl alcohol) (PVA) in water, and
under these conditions a phase inversion is produced, in such a
way that the more hydrophobic components (PMMA segments)
are concentrated in the core, and the hydrophilic components
(bemiparin + PMAETMA sequences) are distributed in the shell
phase. The consequence is the formation of nanoaggregates,
which are stabilised by the complexation between the ionic
sulphate groups of bemiparin and the ammonium ions of the
copolymer entities (Fig. 4b). The PVA acts as an o/w emulsifying
agent to avoid aggregation of nanoparticles.
The nanoparticle formation with the two commercial poly-
mers was carried out in a similar manner; however the PLGA
system does not form core–shell micelles by phase inversion asFig. 5 SEM images of bemiparin loaded NP systems: (a) Eudragit RS PO, (b) PLGA
98/2 PMMA970-b-PMAETMA20.
856 | J. Mater. Chem. B, 2013, 1, 850–860EUDRAGIT and PMMA-b-PMAETMA systems. In the case of
PLGA, nanoparticles were formed by double emulsion instead.
Particle size and zeta potential (ZP) measurements by DLS
The ZP has been used as an index of the NP stability in the
suspension. It can greatly aﬀect the particle stability in suspen-
sion through the electronic repulsion between particles. As a
result, a higher absolute value of the ZP indicates a more stable
suspension, and a lower value implicates colloid instability,
which could lead to aggregation of NPs. Particles prepared with
the cationic systems without bemiparin exhibited strongly posi-
tive zeta potential values in water due to the presence of the
ammonium charge group. PLGA NPs showed a small negative ZP
probably due to the carboxylic end groups of the copolymer chain.
When bemiparin was encapsulated in the nanoparticle the zeta
potential value becamemore negative, which can be attributed to
the presence of bemiparin on the NP surface. Encapsulated
bemiparin not only neutralised the positive charges of Eudragit
RS PO and the RAFT made block copolymers, but also provided a
negative ZP to the loaded NPs. The non-neutralised sulphate
groups provided stability to the NP shell. Table 3 shows the block
copolymer composition inuence on the ZP values obtained. The
higher cationic segment length and the smaller ZP absolute value
are due to a higher charge neutralization between bemiparin and
the corresponding cationic block copolymers. It means a higher
Dh of the NP system. When all the particles in suspension have a
large negative or positive ZP then they will tend to repel each
other and there will be no tendency for the particles to come
together. However, if the particles have low ZP values then the
aggregation is favoured and the Dh obtained is higher.
Size and morphology characterization of the NP systems by
SEM
The morphology of NP systems was determined using Scanning
Electron Microscopy (SEM) and it was predominantly spherical
(Fig. 5). Evidence for the encapsulation of bemiparin was also
provided by EDAX analysis, by means of which the sulfur band in
the NP systems was observed (Fig. 6), and by Fourier Transform
Infrared (FTIR) spectroscopy (ESI†). Non-loaded NPs did not give
a detectable signal of S in the corresponding EDAX. Logically, the, (c) 86/14 PMMA970-b-PMAETMA158, (d) 92/8 PMMA970-b-PMAETMA84, and (e)
This journal is ª The Royal Society of Chemistry 2013
Fig. 6 EDAX analysis at 15 keV of bemiparin loaded NP systems: (a) 86/14 PMMA970-b-PMAETMA158, (b) 92/8 PMMA970-b-PMAETMA84, and (c) 98/2 PMMA970-b-
PMAETMA20.
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View Article Onlinecontribution of the S signal is associated with the initiator linked
at the end of the copolymer chains, and according to the high
molecular weight, the contribution is very small.Table 5 Tg values of the NP systems measured by DSC under nitrogen atmo-
sphere at 10 C min1
Sample Tg1 (C) Tg2 (C)
BEMIPARIN — —
86/14 BLOCK COPOLYMER — 86
Bemiparin loaded 86/14 NPs 39 112
92/8 BLOCK COPOLYMER — 93Encapsulation eﬃciency (EE)
The amount of bemiparin entrapped within the polymeric
nanoparticles was determined by measuring the amount of the
drug released to the external aqueous solution recovered aer
centrifugation and washing the nanoparticles. Summarized in
Table 4, the entrapment eﬃciency within polymeric nanoparticles
was aﬀected by the nature of the polymer. When PMMA-b-
PMAETMA and Eudragit RS PO polymers were used, the
encapsulation eﬃciency of bemiparin was higher than that
observed for a PLGA polymer. Owing to the polyanionic nature of
bemiparin, ionic bonds between the drug and the quaternary
ammonium groups of the polymers led to an increase of bemi-
parin immobilization compared to the PLGA polymer. Consid-
ering the %EE, the mean charge density of bemiparin15 and the
corresponding charge density of the polymer systems, the bemi-
parin encapsulation percentage and the charge ratio of the NP
systems were calculated. These results corroborated the results
obtained by ZP, the higher cationic segment length (PMAETMA)
and the higher neutralization of the bemiparin charges (Table 4).
It is noticeable that the amount of loaded bemiparin is very
similar for all the NP systems analysed (Table 4).Bemiparin loaded 92/8 NPs 36 114
98/2 BLOCK COPOLYMER — 110
Bemiparin loaded 98/2 NPs 38 118
Eudragit RS PO 68.0 —
Bemiparin loaded Eudragit RS PO NPs 44.9 89.2
PLGA 46.9 —
Bemiparin loaded PLGA NPs 47.6 —DSC measurements
PMMA-b-PMAETMA block copolymers showed a unique
thermal transition (Tg) between 86 and 110 C, depending on
the composition. This transition can be attributed to the Tg ofTable 4 % Encapsulation Eﬃciency (EE) of bemiparin loaded NP systems measure
NP system EE-%  SD
mg bemiparin
encapsulateda
Wt-% bem
encapsulat
into the NP
PLGA NPs 89  3 178 15.1
86/14 NPs 98  2 196 16.4
92/8 NPs 96  3 192 16.1
98/2 NPs 95  4 190 16.0
Eudragit RS PO NPs 94  2 188 15.8
a Bemiparin encapsulated ¼ ([mg bemiparin]0 %EE)/100. b %wt bemipa
bemiparin encapsulated] + [mg polymer]). c r ¼ ([g bemiparin]/Mw(bem
disaccharide). d +r ¼ ([g polymer]/Mw(PMMA-b-PMAETMA))  no. of [MAETMA
This journal is ª The Royal Society of Chemistry 2013the MMA segment. The systems showed a decrease of Tg value
as the FPMAETMA was increased in the polymer. This feature can
be due to the plastication eﬀect of the MAETMA segments in
the polymer system.38 However, when loaded NPs were ana-
lysed, two diﬀerent glass transition temperatures were
observed, which belong to the MAETMA and MMA segments
respectively. It can be explained as the result of the interaction
of the ionic drug bemiparin that increases the hydrophilic
segment character and causes a nanodomain segregation of
both blocks. In that case, the Tg values approach those of the
corresponding homopolymers (Table 5).Bemiparin release
Fig. 7 illustrates the in vitro release proles at pH 7.4 obtained
for each formulation of encapsulated bemiparin. All thed by HPLC-UV. Charge densities, +r and r, are apparent relative densities
iparin
ed
sb
r (bemiparin
density charge)  103c
+r (polymer
density charge)  103d r/+r
1.53 — —
1.68 2.39 0.70
1.65 1.31 1.26
1.63 0.36 4.53
1.61 0.33 4.88
rin encapsulated into NPs ¼ ([mg bemiparin encapsulated]  100)/([mg
iparin))  no. of disaccharide units  2.7 (negative density bemiparin/
units].
J. Mater. Chem. B, 2013, 1, 850–860 | 857
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View Article Onlineformulations showed an initial burst release; however the
inuence of the chemical structure of the polymers on the
release prole was evident at longer time points at pH 7.4.
Eudragit RS PO NPs released the least amount of bemiparin
over the 70 day analysis period which was probably due to ionic
interactions between the ammonium groups of the polymer and
the sulphate groups of bemiparin. This polymer system is
hydrophobic as the random distribution of MAETMA along the
polymer chain does not allow phase segregation to occur and
PMMA sequences are dominant. This makes water diﬀusion
more diﬃcult, and therefore the bemiparin release.
At pH 7.4 the highest bemiparin release (nearly 100%)
occurred in PLGA NPs due to the amorphous structure and non-
ionic character of the PLGA polymer. Drug release from PLGA
NPs was mainly controlled by the diﬀusion of bemiparin
throughout the exible chains, and/or erosion mechanisms of
PLGA, as it is a biodegradable polymer. In the rst three weeks,
the bemiparin release prole in a PLGA NP system did not show
a signicant diﬀerence compared to the block copolymer
systems; however aer 25 days the bemiparin release increased
probably due to the higher erosion of PLGA by biodegradation.
Total release of bemiparin was conrmed by dissolution of the
NPs in ethyl acetate and analysis of the bemiparin content by
HPLC-UV and no bemiparin was detected.
Bemiparin release from the cationic block copolymers was
found to be controlled by the three-dimensional network
structure produced by ionic interactions following water diﬀu-
sion into the nanoparticles. This may explain the signicant
retardation of bemiparin release from the Eudragit RS PO
system.
NPs prepared with PMMA-b-PMAETMA copolymers showed a
higher bemiparin release compared to Eudragit RS PO NPs,
due to the microstructure of the copolymers. These block
copolymers formed a self-organised system with a core of
PMMA blocks and a shell of the cationic PMAETMA complexed
with bemiparin (see Fig. 4b). The latter nanodomain is very
hydrophilic and might allow better water diﬀusion compared to
the Eudragit RS PO.
NP block copolymer systems showed a slight inuence of the
copolymer composition on the bemiparin release prole at pHFig. 7 Bemiparin release proﬁle in a buﬀer at pH 7.4 (a) using HPLC-UV detection at
EUDRAGIT NPs, PLGA NPs. Data are presente
858 | J. Mater. Chem. B, 2013, 1, 850–8607.4, since NPs prepared from the 86/14 copolymer presented a
slower release than NPs prepared using the copolymers with
lower content on MAETMA blocks (92/8 and 98/2).Cell proliferation assay
The Baf32 cells provide a measure of the activity of the ternary
complexes formed between bemiparin, FGF2 and FGF receptor
1c. The formation of active ternary complexes induces cell
proliferation which was measured by the MTS assay. The extent
of proliferation is modulated by the concentration of FGF2 and
bemiparin as well as the activity of the bemiparin. As bemiparin
was not chemically modied in each of the polymer systems,
this assay provides a measure of the availability of bemiparin in
the diﬀerent polymer systems. FGF2 or bemiparin alone can
induce the proliferation of the cells; however the presence of
both in an active ternary complex enhances proliferation. This
was observed when the Baf32 cells were exposed to free bemi-
parin in the concentration range of 5–60 nM in the presence or
absence of FGF2 (Fig. 8). There was, however, no dose-depen-
dent increase in the proliferation of the cells in the presence of
increasing concentrations of bemiparin. Bemiparin encapsu-
lated in each of the polymer systems was also analysed by the
Baf32 cell assay where cells were exposed to diﬀerent concen-
trations of the polymer systems based on the amount of
encapsulated bemiparin between 5 and 60 nM. Bemiparin
encapsulated in PLGA NPs showed dose-dependent increase in
cell proliferation with increasing concentrations of encapsu-
lated bemiparin. The highest dose of bemiparin encapsulated
in PLGA NPs was equally as active as free bemiparin (p < 0.05).
This may be due to 40% release of bemiparin from PLGA within
72 h (Fig. 7). Bemiparin encapsulated in Eudragit RS PO was
signicantly less active than free bemiparin (p < 0.05) except at
the highest concentration used and is likely to be attributed to
the low release of bemiparin at 72 h of approximately 10%.
When PMMA-b-PMAETMA block copolymers were used to
encapsulate bemiparin, the systems were signicantly less
active than free bemiparin (p < 0.05) probably due to the ionic
retention of bemiparin with the cationic group of the polymer
carrier. The 98/2 PMMA-b-PMAETMA system became dose-242 nm. 98/2 NPs, 92/8 NPs, 86/14 NPs,
d as mean  SD (n ¼ 3).
This journal is ª The Royal Society of Chemistry 2013
Fig. 8 Proliferation of BaF32 cells expressing FGFR 1c in the presence of bemi-
parin, PLGA containing bemiparin, Eudragit RS PO containing bemiparin, 92/8
PMMA-b-PMAETMA containing bemiparin, 98/2 PMMA-b-PMAETMA containing
bemiparin either in the presence or absence of FGF2. Polymer systems were
analyzed at a range of concentrations based on the amount of encapsulated
bemiparin at the start of the assay. Data are presented as mean  SD and cor-
rected for the proliferation of cells in the presence of medium only (n ¼ 3).
Statistical analysis was performed using a one-way ANOVA, with a p < 0.05. (*)
indicates a signiﬁcant statistical diﬀerence (p < 0.05).
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View Article Onlinedependent as the PLGA system because at pH 7.4 the bemiparin
release in that system was close to 40% at 72 h (Fig. 7).Conclusion
RAFT polymerisation was shown to be a suitable method to
prepare amphiphilic block copolymers of PMMA-b-PMAETMA.
These amphiphilic block copolymers were used as carriers for
the controlled delivery of bemiparin due to their micellar self-
assembled nanoparticles loaded with bemiparin. Loaded NPs
with a mean size between 100 and 200 nm, depending on the
block copolymer composition, were obtained with a predomi-
nantly spherical morphology. Eudragit RS PO was used as a
structural and chemical model with positively charged func-
tions but diﬀerent microstructures. PLGA was taken as a
biodegradable and biocompatible model very commonly used
in drug delivery. RAFT block copolymers showed similar prole
plots for a PLGA system and higher drug release than Eudragit
RS PO. The encapsulated-bemiparin in the PLGA and 98/2 block
copolymer systems showed a dose dependent behavior in cell
proliferation, which was not appreciated in either, Eudragit
RS PO NP system or non-encapsulated bemiparin. The encap-
sulation with the block copolymer system oﬀers a modular
release way for the protection and application of bemiparin as
an activating agent of the function of growth factors.References
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